DelveInsight's 'IGALMI Market Size, Forecast, and Market Insight Report' highlights the details around IGALMI, a sublingual film formulation ...

DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...

Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. Find out why I remain ...

Recursion Pharmaceuticals, Inc.’s RXRX share price has surged by 7.02%, which has investors questioning if this is right time ...

With increasing global diagnosis rates and expanding access in emerging markets, HEMLIBRA is poised for continued growth.

But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies ... but the above data ...

From joint ventures to licensing deals, biotechnology is emerging as a strategic bridge between China and Japan.

In one article, Ledley et al1 compare the profitability of pharmaceutical companies with that of other large companies. The authors used data from 2000 to 2018 on public companies for which ...

We have seen 140 institutional investors add shares of TAK stock to their portfolio, and 133 decrease their positions in their most recent quarter. Here are some of the largest recent moves: Wall ...

Takeda must continue to demonstrate value through outcome-based contracts and cost-effectiveness data. As newer agents with novel mechanisms enter the market, maintaining differentiation and ...